Amsacrine and Continuous-Infusion High-Dose Cytosine Arabinoside as Induction Therapy for Patients with Newly-Diagnosed Acute Myelogenous Leukemia

References

• Ellison R.R., Holland J.R., Weil M., Jacquillat C., Boiron M., Bernard J., Sawitsky A., Rosner F., Gussoff B., Silver R.T., Karanas A., Cuttner J., Spurr C.L., Hayes D.M., Blom J., Leone L.A., Haurani R., Kyle R., Hutchinson J.L., Forcier R.J., Moon J.H. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood 1968; 32: 507–523
   PubMed Web of Science ®Google Scholar
• Keating M.J., McCredie K.B., Bodey G.P., Smith T.L., Gehan E., Freireich E.J. Improved prospects for long term survival in adults with acute myelogenous leukemia. JAMA 1982; 248: 2481–2486
   PubMed Web of Science ®Google Scholar
• Gale R.P., Cline M.J. High remission induction rate in acute myeloid leukemia. Lancet 1977; 1: 497–499
   PubMed Web of Science ®Google Scholar
• Yates J.W., Wallace H.J., Ellison R.R., Holland J.F. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Treat. Rep. 1973; 57: 485–88
   Google Scholar
• Keating M., Gehan E., Smith T., Estey E.H., Walters R.S., Kantarjian H.M., McCredie K.B., Freireich E.J. A strategy for evaluation of new treatments in untreated patients: application to a clinical trial of AMSA for acute leukemia. J. Clin. Oncol. 1987; 5: 710–721
   PubMed Web of Science ®Google Scholar
• Cassileth P.A., Katz M.E. Chemotherapy for adult acute nonlymphocytic leukemia with daunorubicin and cytosine arabinoside. Cancer Treat. Rep. 1977; 61: 1441–1445
   PubMedGoogle Scholar
• Yates J., Glidewell O., Wilernik P., Cooper M.R. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 1982; 60: 454–462
   PubMed Web of Science ®Google Scholar
• Ghaddar H., Plunkett W., Kantarjian H., Pierce S., Freireich E., Keating M., Estey E. Long term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion cytosine arabinoside. Leukemia 1994; 8: 1269–1274
   PubMed Web of Science ®Google Scholar
• Plunkett W., Liliemark J.O., Adams T.M., Nowak B., Estey E., Kantarjian H., Keating M.J. Saturation of 1—D-ara-binofuranosylcytosine 5ø-triphosphate accumulation in leukemic cells during high-dose 1—D-arabinofuranosylcytosine therapy. Cancer Res. 1987; 47: 3005–3011
   PubMed Web of Science ®Google Scholar
• Heinemann V., Estey E., Keating M.J., Plunkett W. Patient-specific dose rate for continuous infusion high-dose cytara-bine in relapsed acute myelogenous leukemia. J. Clin. Oncol 1989; 7: 622–628
   PubMed Web of Science ®Google Scholar
• Kessel D., Hall T.C. Transport and phosphorylation as factors in antitumor action of cytosine arabinoside. Science 1967; 156: 1240–1241
   PubMed Web of Science ®Google Scholar
• Kufe D.W., Spriggs D., Egan E.M., Munroe D. Relationship among ara-CTP pools, formation of (ara-C) DNA, and cytotoxicity of human leukemic cells. Blood 1984; 64: 54–58
   PubMed Web of Science ®Google Scholar
• Legha S.S., Keating M.J., McCredie K.B., Bodey G.P., Freireich E.J. Evaluation of AMSA in previously treated patients with acute leukemia: Results of therapy in 109 adults. Blood 1982; 60: 484–490
   PubMed Web of Science ®Google Scholar
• Breman E., Arlin Z.A., Gaynor J., Miller W., Gee T., Kempin S.J. Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol. Leukemia 1989; 3: 115–121
   PubMed Web of Science ®Google Scholar
• Arlin Z.A., Ahmed T., Mittelman A., Feldman E., Mehta R., Weinstein P. A new regimen with high-dose cytarabine is safe and effective therapy for acute leukemia. J. Clin. Oncol. 1987; 5: 371–375
   PubMed Web of Science ®Google Scholar
• Arlin Z.A., Feldman E.J., Mittelman A., Ahmed T., Puccio C., Chun H.G. Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia. Cancer 1991; 68: 1198–1200
   PubMed Web of Science ®Google Scholar
• Watson A.M., Seymour J., Lee N., Whiteside M., Firkin F. An effective age-unrestricted m-AMSA-based second-line regimen for poor prognosis acute myeloid leukaemia. Eur. J. Haematol. 1994; 52: 80–86
   PubMed Web of Science ®Google Scholar
• Jehn U., Heinemann V. Phase-II study of treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrine. Ann Hematol 1993; 66: 131–134
   PubMed Web of Science ®Google Scholar
• Estey E., Smith T.L., Keating M.J., McCredie K.B., Gehan E.A., Freireich E.J. Prediction of survival during induction therapy in patients with newly diagnosed acute myelogenous leukemia. Leukemia 1989; 3: 257–263
   PubMed Web of Science ®Google Scholar
• Keating M.J., Smith T.L., Kantarjian H., Cork A., Walters R., Trujillo J.M., McCredie K.B., Gehan E.A., Freireich E.J. Cytogenetic pattern in acute myelogenous leukemia: A major reproducible determinant of outcome. Leukemia 1988; 2: 403–112
   PubMed Web of Science ®Google Scholar
• Bloomfield C. Prognostic factors for selecting curative therapy for adult acute myeloid leukemia. Leukemia 1992; 6(4 suppl)65–67
   PubMedGoogle Scholar
• Bloomfield C.D., Lawrence D., Arthur D.C., Berg D.T., Schiffer C.A., Mayer R.J. Curative impact of intensification with high-dose cytarabine (HiDAC) in acute myeloid leukemia (AML) varies by cytogenetic group. Blood 1994; 84(suppl 1)111a
   PubMed Web of Science ®Google Scholar
• Avvisati G., Mandelli F., Petti M.C., Vegna M.L., Spadea A., Liso V., Specchia G., Bernasconi C., Alessandrino E.P., Piatti C., Carella A.M. Idarubicin (4-demethoxydaunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia: a pilot study of the Italian Cooperative Group GIMENA. Eur. J. Haematol 1990; 44: 257–260
   PubMed Web of Science ®Google Scholar